Clorox (NYSE:CLX) Price Target Raised to $170.00 at Citigroup

Clorox (NYSE:CLX) had its target price upped by equities research analysts at Citigroup from $165.00 to $170.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Citigroup’s price objective indicates a potential upside of 3.19% from the stock’s previous close.

Several other brokerages also recently issued reports on CLX. Barclays raised their price objective on shares of Clorox from $122.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Argus raised shares of Clorox to a “hold” rating in a research report on Tuesday, June 4th. Wells Fargo & Company decreased their target price on Clorox from $135.00 to $130.00 and set an “underweight” rating on the stock in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft upped their price target on Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Finally, TD Cowen initiated coverage on Clorox in a report on Tuesday, July 23rd. They set a “sell” rating and a $122.00 price objective on the stock. Six investment analysts have rated the stock with a sell rating and thirteen have given a hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $143.50.

Clorox Stock Down 0.0 %

Clorox stock opened at $164.75 on Friday. The company has a debt-to-equity ratio of 5.04, a current ratio of 1.03 and a quick ratio of 0.63. Clorox has a fifty-two week low of $114.68 and a fifty-two week high of $166.49. The firm has a fifty day moving average price of $142.93 and a two-hundred day moving average price of $142.85. The firm has a market cap of $20.46 billion, a price-to-earnings ratio of 85.36, a P/E/G ratio of 3.21 and a beta of 0.40.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, August 1st. The company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.28. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Clorox had a return on equity of 281.12% and a net margin of 3.95%. As a group, analysts forecast that Clorox will post 6.56 earnings per share for the current year.

Institutional Trading of Clorox

Several hedge funds have recently modified their holdings of CLX. Northwest Financial Advisors acquired a new stake in Clorox during the 4th quarter valued at $29,000. Core Wealth Advisors Inc. acquired a new stake in shares of Clorox in the fourth quarter valued at $29,000. Innealta Capital LLC bought a new position in shares of Clorox in the second quarter valued at about $30,000. Trifecta Capital Advisors LLC lifted its position in Clorox by 139.8% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock worth $30,000 after buying an additional 130 shares in the last quarter. Finally, First United Bank & Trust bought a new stake in Clorox during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.